[1] |
Hnatowich DJ. Antisense and nuclear medicine[J]. J Nucl Med, 1999, 40:693-703.
|
[2] |
Dewanjee MK, Abdol KG, Kapadvanjwala M, et al.Noninvasive imaging of c-myc oncogene messenger RNA with Indium-111-antisense probes in a mammary tumor-bearing mouse model[J]. J Nucl Med, 1994, 35:1054-1063.
|
[3] |
Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, et al. Noninvasive imaging of c-erbB2 oncogen mRNA of breast tumor in mouse model with In-111 labeled antisens oligonucleotide[J]. J Nucl Med, 1994, 35:65.
|
[4] |
Urbain JC, Shore SK, Vekemans MC, et al. Scintigraphic imaging of oncogens with antisense probes:does it make sense?[J]. Eur J Nucl Med, 1995, 22:499-504.
|
[5] |
Hnatowich DJ, Winnard P, Virzi F, et al. Technetium-99m labeling of DNA oligonucleotides[J]. J Nucl Med, 1995, 36:2306-2314.
|
[6] |
Winnard P, Chang F, Rusckowski M, et al. Preparation and use of NHS-MAG3 for Technetium-99m labeling of DNA[J]. Nucl Med Biol, 1997, 24:425-432.
|
[7] |
Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides[J]. Biochim Biophys Acta, 1999, 1489(1):53-68.
|
[8] |
Diasio RB, Zhang R. Pharmacology of therapeutic oligonucleotides. Antisense[J]. Nucleic Acid Drug Dev, 1997, 7:239-243.
|
[9] |
Mardirossian G, Lei K, Rusckowski M, et al. In vivo hybridization of Technitium-99m-labeled peptide nucleic acid(PNA)[J]. J Nucl Med, 1997, 38:907-913.
|
[10] |
Lu xiao-ming, Fischman AJ, Jyawook SL, et al. Antisense DNA delivery in vivo:liver targeting by receptor-mediated uptake[J]. J Nucl Med, 1994, 35:269-275.
|
[11] |
Dadon J, Blum HE. Receptor-mediated delivery of hepatitis B virus DNA and antisense oligodeoxynucleotides to avian liver cells[J]. Hepatology, 1996, 24:474-481.
|
[12] |
De Oliveira MC, Boutet V, Fattal E, et al. Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice[J]. Life Sci, 2000, 67(13):1625-1637.
|
[13] |
David DFM, Wei Ai-qun. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes[J]. Leuk Res, 1996, 20:925-930.
|
[14] |
Sczakiel G. Theoretical and experimental approaches to design effective antisense oligonucleotides[J].Front Biosci, 2000, 5:D194-D201.
|
[15] |
Larsen HJ, Bentin T, Nielsen PE. Antisense properties of peptide nucleic acid[J]. Biochim Biophys Acta, 1999, 1489(1):159-166.
|
[16] |
Lubrich B, Calker D, Peschka SR. Inhibition of inositol uptake in astrocytes by antisense oligonucleotides delivered by pH-sensitive liposomes[J]. Eur J Biochem, 2000, 267(8):2432-2438.
|
[17] |
Hu RH, Chu SH. Suppression of tumor necrosis factor secretion from white blood cells by synthetic antisense phosphorothioate oligodeoxynucleotides[J]. Int J Immunopharmacol, 2000, 22(6):445-452.
|